Shares of STAAR Surgical (NASDAQ:STAA) have been assigned a consensus broker rating score of 2.00 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating and two have assigned a strong buy rating to the company.
Analysts have set a one year consensus target price of $17.67 for the company and are forecasting that the company will post $0.03 EPS for the current quarter, according to Zacks. Zacks has also given STAAR Surgical an industry rank of 95 out of 265 based on the ratings given to its competitors.
A number of research firms have commented on STAA. Benchmark reissued a “buy” rating and issued a $21.00 target price on shares of STAAR Surgical in a report on Monday, November 20th. BidaskClub lowered STAAR Surgical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Canaccord Genuity lifted their target price on STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 17th. Finally, Zacks Investment Research lowered STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th.
In related news, VP Keith Holliday sold 6,000 shares of STAAR Surgical stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total value of $99,900.00. Following the completion of the sale, the vice president now owns 45,969 shares of the company’s stock, valued at $765,383.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu KCG Holdings LLC bought a new stake in shares of STAAR Surgical in the second quarter worth $118,000. Prudential Financial Inc. bought a new stake in shares of STAAR Surgical in the third quarter worth $138,000. Stephens Inc. AR grew its holdings in shares of STAAR Surgical by 2.6% in the second quarter. Stephens Inc. AR now owns 12,238 shares of the medical instruments supplier’s stock worth $132,000 after acquiring an additional 315 shares during the period. Citadel Advisors LLC bought a new stake in shares of STAAR Surgical in the third quarter worth $172,000. Finally, Simplex Trading LLC grew its holdings in shares of STAAR Surgical by 44.3% in the third quarter. Simplex Trading LLC now owns 18,435 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 5,656 shares during the period. 77.70% of the stock is owned by institutional investors.
STAAR Surgical (NASDAQ STAA) traded up $0.05 during trading on Friday, hitting $16.20. The company’s stock had a trading volume of 49,710 shares, compared to its average volume of 80,778. The company has a market cap of $658.63, a price-to-earnings ratio of -324.00 and a beta of 1.19. STAAR Surgical has a twelve month low of $8.95 and a twelve month high of $17.60. The company has a current ratio of 2.24, a quick ratio of 1.72 and a debt-to-equity ratio of 0.02.
ILLEGAL ACTIVITY NOTICE: “” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thestockobserver.com/2018/01/12/915435.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.